Leading pharma company Bristol-Myers Squibb Company’s (BMY) revenue beat analyst estimates by 0.3%, while its EPS came 8.5% above the consensus estimate.
Despite the macroeconomic headwinds, the company maintained its prior guidance for the current fiscal year, 2022. Its total sales are expected to be $46 billion, and non-GAAP EPS is expected to come between $7.44 and $7.74 in the current fiscal year.
